Thesis
Two positive Phase 3 trials and a priority voucher put COMP360 at the FDA door — approval plus DEA rescheduling must both clear for a commercial launch
COMP360 (psilocybin therapy) backed by two Phase 3 wins in treatment-resistant depression across more than 1,000 patients, with durable benefit through 26 weeks, is now under rolling FDA review accelerated by a National Priority Voucher. The thesis resolves on whether FDA grants approval and DEA completes rescheduling, since both are required before a commercial launch can occur. The novel modality, a single-administration psychedelic requiring supervised clinical settings, creates an untested reimbursement and site-of-care infrastructure risk that conventional antidepressant approvals have never faced.
Focus
NDA submission for COMP360 in TRD
Q4 2026
Bull
Final NDA submission completes in Q4 2026 on schedule, incorporating COMP005 and COMP006 Phase 3 data along with the 26-week durability package, triggering the CNPV-accelerated review window. A complete, well-organized rolling submission with no deficiencies positions FDA to issue approval within 1–2 months of final filing, clearing the first of the two thesis-defining hurdles (FDA approval plus DEA rescheduling) and setting the stage for a commercial launch.
Bear
FDA issues a Refuse-to-File or a Complete Response Letter citing deficiencies in the chemistry, manufacturing, and controls package, the REMS design for psychedelic-assisted therapy, or the clinical dataset — particularly if regulators view the MADRS response rates across the two trials (39% in COMP006, 25% in COMP005) as insufficiently consistent or clinically meaningful. A request for additional data or a third trial would materially extend the timeline and pressure the cash runway, even if it extends into 2028.
Unlock the full thesis for CMPS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.